Home » Stocks » SPPI

Spectrum Pharmaceuticals, Inc. (SPPI)

Stock Price: $3.22 USD 0.00 (0.00%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $3.23 +0.01 (0.31%) Jul 30, 7:49 PM
Market Cap 528.42M
Revenue (ttm) 109.33M
Net Income (ttm) -155.99M
Shares Out 164.11M
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $3.22
Previous Close $3.22
Change ($) 0.00
Change (%) 0.00%
Day's Open 3.20
Day's Range 3.19 - 3.30
Day's Volume 1,135,115
52-Week Range 2.82 - 5.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Investors need to pay close attention to for Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals today presented an e-poster on poziotinib CNS activity in patients with NSCLC EGFR or HER2 exon 20 mutations at ASCO.

1 month ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals announces that the FDA is “on site” for the ROLONTIS® (eflapegrastim) manufacturing facility inspection.

2 months ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals to present poster for poziotinib in brain mets at upcoming ASCO Annual Meeting beginning on June 4 2021.

2 months ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals (SPPI) to participate in the Jefferies and JMP Securities investor conferences in June.

2 months ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update

2 months ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $sppi--Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update

2 months ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #AACR--Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021

3 months ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #AACR--Spectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing Data

3 months ago - Business Wire

Reddit stocks always make noise across social media platforms. But these investments have serious catalysts connected to them.

Other stocks mentioned: CTRM, CVM, MMEDF, MRO, YCBD
4 months ago - InvestorPlace

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI #earnings--Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update

4 months ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

4 months ago - Business Wire

HENDERSON, Nev.--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection

4 months ago - Business Wire

The FDA grants a Fast Track designation to Spectrum Pharmaceuticals' (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.

4 months ago - Zacks Investment Research

These penny stocks have more than just a low price point. They have Wall Street analysts backing up those prices with high price targets.

Other stocks mentioned: ATNX, BLU, CPRX, NBEV, OPK, UEC
4 months ago - InvestorPlace

Spectrum Pharma is down due to two resolvable issues. If the Rolontis PDUFA issue is resolved, the stock may shoot up.

8 months ago - Seeking Alpha

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Spectrum Pharmaceuticals (SPPI) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Investors need to pay close attention to Spectrum (SPPI) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 12.12% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

The company announced the pricing of a public offering of common stock.

1 year ago - The Motley Fool

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) announced good news for cancer patients in its midstage trial on Tuesday.

1 year ago - 24/7 Wall Street

Spectrum scores a key win in the clinic with its experimental lung cancer drug.

1 year ago - The Motley Fool

These hidden gems have the potential to deliver significant returns to their shareholders over the long run.

Other stocks mentioned: XNCR
1 year ago - The Motley Fool

Spectrum Pharma (SPPI) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joseph Turgeon on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

Shares jumped even though the company reported disappointing earnings. What can explain the boost?

1 year ago - The Motley Fool

Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals, Inc.'s (SPPI) CEO Joseph Turgeon on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Progress of its pipeline candidates is likely to have increased Spectrum Pharmaceuticals' (SPPI) operating expenses in the fourth quarter.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals (SPPI) closed the most recent trading day at $3.24, moving -1.52% from the previous trading session.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals: Stock Price Drop Vs Disappointing Clinical Data Provides Good Upside

1 year ago - Seeking Alpha

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), which plummeted 60% to $3.50 Thursday in reaction to a negative clinical readout, were rebounding Friday.

1 year ago - Benzinga

Spectrum Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) shares were halved on Thursday after the firm provided an update on its midstage cancer study.

1 year ago - 24/7 Wall Street

Spectrum Pharmaceuticals Inc. shares fell 17% in premarket trade Thursday after the company said a mid-stage trial of a treatment for non-small cell lung cancer, or NSCLC, missed its main goal.

1 year ago - Market Watch

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Spectrum Pharmaceuticals.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joseph Turgeon on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Spectrum Pharma (SPPI) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

Early ORR results in NSCLC with exon 20 mutation for lead candidate poziotinib pushed the stock over $20.00/share in 2018.

1 year ago - Seeking Alpha

Early ORR results in NSCLC with exon 20 mutation for lead candidate poziotinib pushed the stock over $20.00/share in 2018.

1 year ago - Seeking Alpha

About SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with... [Read more...]

Industry
Biotechnology
IPO Date
Sep 26, 1996
Stock Exchange
NASDAQ
Ticker Symbol
SPPI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SPPI stock is "Buy." The 12-month stock price forecast is 9.80, which is an increase of 204.35% from the latest price.

Price Target
$9.80
(204.35% upside)
Analyst Consensus: Buy